Monday, May 23, 2022 9:13:57 PM
Hi my Friend Rockleo , ..with the biggest respect, but I just feel little different here about Dr Pestell.
He came to CYDY when the person in charge was Antony C , our Chairman of the Board.
I still remember when in November 2018 PR he introduced Dr Pestell to us , and how lucky we are to have him ..
And I felt very lucky..I was so hopeful....
And then during the next few CCs Dr Pestell was explaining to us about his accomplishments in CCR5 and cancers , and about his best ever prostate cancer test he is developing , will only need one biopsy instead of 12 , and it will show a physician if particular patient need an aggressive treatment or not.
I remember how impressed I was , what a big advance in a prostate cancer , diagnosis and treatment.
And Dr Pestell told us during few CCs , that his test will be ready in 6-8 months , and it should bring 500K-1 B doll to CYDY..
We were all sitting and calculating how many studies CYDY may be able to do for that much of money..
And where is this test ?? ..Why no one is talking about anymore ..?
And then November 2018 our Chairman of the Board made Dr Pestell CMO and in charge of the cancer study.
He just needed to design a protocol , start and supervise this study..
It was November 2018 , so why he wrote to court end of 2019 that Dr NP was pushing him to enroll patients in July 2019 , but his protocol was still not safe..
Why his protocol was not safe 8 months after he started to design it ??
Why ??
What was he doing from November 2018 , he should call few of us here , and we would help him to design a safe protocol.
And after all the studies, and dose justification in HIV , the same thing was not needed in cancer , as we didn't need to do it in Nash..
But he put us into this dose justification in cancer , with no reason imo , , so first for 8-9 months he didn't accomplished much in our cancer study , not one enrolled patient , but then after he was gone we were stock for 2 years doing dose justification...
Why we didn't do it in NASH , because it was not needed anymore , as it was not needed already in cancer..
But it is what it is ..Company settle , and I think it is for the best , and I feel our company is closing many doors now so a BO or multi-partnerships will be here any time now .
Of course this is nothing but my very strong feeling after the last CC , when DR Kelly said they have few NDAs , and they looking for a partners , especially in NASH , LH , Cancers and HIV..
Entire world need help in LH NOW , so I expect all this is coming very SOON .. ..
I am very positive after today PR..
I think good ending for our great molecule is very close..
All IMO.
He came to CYDY when the person in charge was Antony C , our Chairman of the Board.
I still remember when in November 2018 PR he introduced Dr Pestell to us , and how lucky we are to have him ..
And I felt very lucky..I was so hopeful....
And then during the next few CCs Dr Pestell was explaining to us about his accomplishments in CCR5 and cancers , and about his best ever prostate cancer test he is developing , will only need one biopsy instead of 12 , and it will show a physician if particular patient need an aggressive treatment or not.
I remember how impressed I was , what a big advance in a prostate cancer , diagnosis and treatment.
And Dr Pestell told us during few CCs , that his test will be ready in 6-8 months , and it should bring 500K-1 B doll to CYDY..
We were all sitting and calculating how many studies CYDY may be able to do for that much of money..
And where is this test ?? ..Why no one is talking about anymore ..?
And then November 2018 our Chairman of the Board made Dr Pestell CMO and in charge of the cancer study.
He just needed to design a protocol , start and supervise this study..
It was November 2018 , so why he wrote to court end of 2019 that Dr NP was pushing him to enroll patients in July 2019 , but his protocol was still not safe..
Why his protocol was not safe 8 months after he started to design it ??
Why ??
What was he doing from November 2018 , he should call few of us here , and we would help him to design a safe protocol.
And after all the studies, and dose justification in HIV , the same thing was not needed in cancer , as we didn't need to do it in Nash..
But he put us into this dose justification in cancer , with no reason imo , , so first for 8-9 months he didn't accomplished much in our cancer study , not one enrolled patient , but then after he was gone we were stock for 2 years doing dose justification...
Why we didn't do it in NASH , because it was not needed anymore , as it was not needed already in cancer..
But it is what it is ..Company settle , and I think it is for the best , and I feel our company is closing many doors now so a BO or multi-partnerships will be here any time now .
Of course this is nothing but my very strong feeling after the last CC , when DR Kelly said they have few NDAs , and they looking for a partners , especially in NASH , LH , Cancers and HIV..
Entire world need help in LH NOW , so I expect all this is coming very SOON .. ..
I am very positive after today PR..
I think good ending for our great molecule is very close..
All IMO.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
